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OBJECTIVE: Numerous recent studies suggest that abnormal intracellular calcium concentration ([Ca2+]i) is a
common defect in diabetic animal models and patients. Abnormal calcium handling is an important mechanism
in the defective pancreatic b-cell function in type 2 diabetes. T-type Ca2+ channel antagonists lower blood
glucose in type 2 diabetes, but the mechanism remains unknown.
METHODS: We examined the effect of the Ca2+ channel antagonist mibefradil on blood glucose in male db/db
mice and phenotypically normal heterozygous mice by intraperitoneal injection.
RESULTS: Mibefradil (15 mg/kg, i.p., b.i.d.) caused a profound reduction of fasting blood glucose from
430.92¡20.46 mg/dl to 285.20¡5.74 mg/dl in three days. The hypoglycemic effect of mibefradil was
reproduced by NNC 55-0396, a compound structurally similar to mibefradil but more selective for T-type Ca2+
channels, but not by the specific L-type Ca2+ channel blocker nicardipine. Mibefradil did not show such
hypoglycemic effects in heterozygous animals. In addition, triglycerides, basal insulin and food intake were
significantly decreased by mibefradil treatment in the db/dbmice but not in the controls. Western blot analysis,
immunohistochemistry and immunofluorescence staining showed a significantly increased expression of T-type
Ca2+ channel a-subunits Cav3.1 and Cav3.2 in liver and brain tissues from db/db mice compared to those from
heterozygous animals.
CONCLUSIONS: Collectively, these results suggest that T-type Ca2+ channels are potential therapeutic targets for
antidiabetic drugs.
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& INTRODUCTION
The hallmark of type 2 diabetes mellitus is chronic
hyperglycemia under both fasting and postprandial condi-
tions. Numerous recent studies in diabetic animal models
and patients suggest that abnormal intracellular calcium
concentration ([Ca2+]i) is a common defect in both insulin-
dependent (type 1) and insulin-independent (type 2)
diabetes (1). Abnormal calcium handling is an important
mechanism in the defective pancreatic b-cell function in
type 2 diabetes (2). Dysregulation of [Ca2+]i may represent a
common factor underlying metabolic, cardiovascular, ocular
and neural complications of diabetes mellitus (3). Clinical
administration of an L-type Ca2+ antagonist has produced
no detrimental or beneficial effects on glucose tolerance
(4,5). Cerebrocrast, an L- and T-type calcium channel
inhibitor, decreases blood glucose and food intake and
increases glucose uptake by the brain (6,7). However, the
specific effects of T-type Ca2+ channel antagonists on blood
glucose regulation remain unknown.
T-type Ca2+ channels are different from other types of Ca2+
channels with regard to their kinetics, pharmacological
properties and activation/inactivation voltage range (8,9). T-
type Ca2+ currents have been described in human pancreatic
islet cells (10,11). Studies on human islets have shown that a
desensitization of glucose-induced insulin secretion is asso-
ciated with [Ca2+]i elevation (12). T-type Ca
2+ current density
and the channels’ mRNA levels increase markedly in rat
pancreatic islets treated with high glucose (13).
Mibefradil blocks both L-type and T-type Ca2+ channels
(14). Clinically, mibefradil has significant therapeutic advan-
tages in reducing blood pressure (15,16), preventing blood
pressure-related arterial hypertrophy (17), lowering heart
rate (18) and preventing and reducing hyperinsulinemia (19).
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An analog of mibefradil, (1S,2S)-2-(2-(N-[(3-benzoimidazol-2-
yl)propyl]-N-methylamino) ethyl)-6-fluoro 1,2,3,4-tetrahydro-1-
isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride
[NNC 55-0396], is more selective for T-type Ca2+ channels (20).
The molecular structure of NNC55-0396 is more similar to that
of mibefradil than to that of the L-type Ca2+ channel blocker
nicardipine (Figure 1). The clinical effect of NNC 55-0396 is
unclear.
& MATERIALS AND METHODS
Experimental animals
Experimental (male BKS Cg-Dock 7 m+/+Lepr/J, db/db,
36–40 g) and control (male Dock7m+/+Leprdb, db/+, hereafter
‘‘wild-type’’, 23–26 g) eight-week-old mice purchased from
Jackson Laboratory (Bar Harbor, ME) were randomly divided
into two main groups. The mice were further randomly
separated into two sub-groups, for a total of four groups
(n = 6 mice per group): the control placebo group, control
drug intervention group, db/db placebo group and db/db
drug intervention group. Mice from both drug intervention
groups were injected with mibefradil (i.p., 15 mg/kg per
injection, b.i.d, for all experiments; Sigma-Aldrich, St. Louis,
MS) in 100 ml normal saline with 0.05% DMSO. Normal saline
with 0.05% DMSO was given to both placebo groups in an
identical manner. During the drug intervention, fasting blood
glucose (food deprivation for eight hours), blood pressure,
body weight, food intake and insulin tolerance (by insulin
tolerance test (ITT)) were continually measured. At the end of
treatments, blood, liver and brain samples were collected.
The animal experimental protocol was approved by the
Institutional Animal Care and Use Committee of the Third
Military Medical University. The organs of the animals were
removed for histochemical analysis after euthanasia.
Immunoassay for insulin, glycosylated hemoglobin
A1c and total cholesterol measurements
Mouse cardiac blood (0.8 ml) was stored at 4 C˚ for three to
four hours. After coagulation and clot retraction, samples
were centrifuged at X1,000g for ten minutes, and serum was
stored at 220 C˚ for later use. Serum basal insulin was
measured using an insulin ELISA kit from Merodia (Uppsala,
Sweden); HbA1c and total cholesterol were measured by
using ELISA kits from R&D Systems (Minneapolis, MN).
Western blot analysis
The tissue samples (50 mg) were homogenized in lysis
buffer (Thermo Fisher Scientific Inc, Waltham, MA) contain-
ing a protease inhibitor cocktail (Roche, Basel, Sweden) and
then centrifuged at X9,000g rpm for 15 minutes at 4 C˚. The
supernatants were denatured and loaded for electrophoresis
at a volume containing 90 mg total protein. After separation,
the proteins were transferred to polyvinylidene fluoride
(PVDF) membranes. Blotted membranes were incubated
overnight with primary antibodies against ß-tubulin (Santa
Cruz Biotechnology Inc, Santa Cruz, CA, 1:200), a1G (Bioss,
China, 1:200) and a1H (Santa Cruz Biotechnology Inc,
1:200). The membranes were then incubated with appro-
priate secondary antibodies at room temperature for
1.5 hours before detection with a chemiluminescence kit
(Beyotime, BeyoECL Plus, China).
Immunohistochemical analysis
The expression levels of Cav3.1 and Cav3.2 were
evaluated using standard immunohistochemistry methods.
Figure 1 - Chemical structure of calcium channel blockers.
Figure 2 - The hypoglycemic and hypolipidemic effects of Ca2+ channel antagonists in db/dbmice. A) Time-dependent changes in blood
glucose concentration during drug treatment. B) Serum HbA1c in mice with and without mibefradil injection. C) Serum total
cholesterol in mice with and without mibefradil injection. Abbreviations: WT, nondiabetic wild-type mice; db/db, db/db mice; NS,
normal saline; Mib, mibefradil; NNC, NNC 55-0396; Nic, nicardipine. * p,0.05, n =6, compared with WT NS group; ** p,0.05, n =6,
compared with NS group of the same type of mice at the same time. Statistical analyses were performed with Student’s t-test (A) or
ANOVA (B and C) according to the specific application.
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Fresh tissue samples were washed with PBS, followed by
paraformaldehyde fixation (4%) and paraffin embedding. The
samples were sliced into 4 mm serial sections for xylene
dewaxing and alcohol dehydration. After blocking nonspecific
antigens with goat serum, the samples were incubated over-
night at 4 C˚ with diluted primary antibodies (50 ml). Then,
biotin-labeled secondary antibodies were added for incubation
at room temperature for one hour in the dark. The samples were
then stained with DAPI for five minutes in the dark, dried and
sealed with anti-fluorescence quenching mounting medium
and kept at 4 C˚ in the dark. Samples without primary
antibodies were employed as negative controls.
Statistical analysis
All data are expressed as the mean ¡ SEM. Statistical
analyses were performed with Student’s t-test or ANOVA
according to the specific application. P-values #0.05 were
considered significant. Data were organized with Adobe
Illustrator CS3 and analyzed with SPSS 17.0 (Statistical
Product and Service Solutions, IBM, Chicago, USA). Statistical
significance for Western blot experiments was determined by
analyzing gray-level values using Quantity One software.
& RESULTS
The effects of Ca2+ channel antagonists on blood glucose
were examined in db/db mice. As shown in Figure 2A,
mibefradil (15 mg/kg, b.i.d) intraperitoneal injection sig-
nificantly decreased blood glucose concentration from
430.92¡20.46 mg/dl to 285.20¡5.74 mg/dl (n = 6, p,0.05)
by day 3. Fasting blood glucose decreased to a level similar
to that of wild-type controls at day 5. The injection of normal
saline (with 0.05% DMSO vehicle) had no effect on blood
glucose in db/db mice. The application of NNC 55-0396, an
antagonist that is more specific to the T-type Ca2+ channel
(21) at the same dose (15 mg/kg, b.i.d), also effectively
reduced blood glucose. In contrast, the L-type Ca2+ channel
blocker nicardipine (12.5 mg/kg, b.i.d) had no significant
effect on blood glucose when administered at a concentra-
tion commonly used for in vivo study (22). These results
indicate that Ca2+ channel antagonists have a profound
blood glucose-lowering effect in db/db mice, and this effect
is likely attributed to the inhibition of T-type Ca2+ channels
rather than any effects on L-type Ca2+ channels. The
application of mibefradil, NNC 55-0396 or nicardipine for
one week had no significant effect on fasting blood glucose
in wild-type mice (Figure 2A), indicating that the effects of
T-type Ca2+ channel blockers are specific to the db/db mice.
The effects of T-type Ca2+ channel blockers on blood
glucose were also evaluated by measuring hemoglobin
glycosylation in db/db and wild-type mice. Similar to the
above results, mibefradil effectively reduced HbA1c in
db/db mice from 301.5¡9.50 to 236.9¡9.83 (p,0.05, n = 6;
Figure 2B). Interestingly, mibefradil slightly reduced HbA1c
Figure 3 - Effects of mibefradil on insulin sensitivity and basal insulin release in diabetic and nondiabetic mice. A and B) Glucose
disposal measured by insulin tolerance test (ITT) before (A) and after (B) mibefradil treatment for seven days. C) Difference in the area
under the curve before and after drug injection. D) Effect of mibefradil on basal insulin in diabetic and nondiabetic mice. * p,0.05,
n =6, compared with WT NS group; ** p,0.05, n=6, compared with NS group of the same type of mice at the same time. Statistical
analyses were performed with Student’s t-test (D) or ANOVA (C), according to the specific application.
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in wild-type animals (from 250.0¡8.28 to 221.7¡4.50 nmol/
L, p,0.05, n = 6), which indicates a physiological role for T-
type Ca2+ channels in glucose regulation in normal mice.
The effect of mibefradil on blood triglycerides was
evaluated in db/db mice. Figure 2C shows that after one
week of mibefradil treatment, plasma cholesterol was
significantly reduced (p,0.05, n = 6) in a manner similar to
the reduction of blood glucose. In contrast, there was no
significant change in cholesterol level between the wild-type
mice with and without the treatment with mibefradil.
Cholesterol was significantly different between db/db and
wild-type control groups (p,0.05, n = 6).
To delineate the mechanism underlying the effects of T-
type Ca2+ channel antagonists on blood glucose in db/db
mice, an ITT was performed after six hours of fasting. Mice
were injected intraperitoneally with porcine insulin (Xinbai
Pharmaceutical, Nanking, China) at 0.75 unit/kg of body
weight. Blood glucose was measured from tail bleeds taken
at the indicated times. Figures 3A and 3B show the results of
ITTs before and after three days of mibefradil injection in
wild-type and db/db mice. The ITT results show no
significant difference in the glucose tolerance in response
to insulin stimulation between the mibefradil-treated and
saline-treated groups (Figures 3A, 3B, 3C). This similar
response may be attributed to the existing high level of
insulin in the db/db mice, which may have attenuated the
effects of further insulin application. In contrast, basal
insulin (after food deprivation for eight hours) in db/db mice
was significantly reduced by seven days of treatment with
mibefradil, from 4.80¡0.35 to 3.21¡0.12 ng/ml (p,0.05,
n = 6) (Figure 3D). This finding indicates that T-type Ca2+
channel antagonists suppress insulin release from pancrea-
tic b-cells of db/db mice. Therefore, T-type Ca2+ channels
may play a role in the pathogenesis of hyperinsulinemia in
this type 2 diabetic model.
The maintenance of the basal glucose level is regulated by
the release of glucose from the liver and the uptake of
glucose into muscle, adipose and brain tissue. The profound
blood glucose-lowering effect of T-type Ca2+ channel
Figure 4 -Western blot analysis of T-type Ca2+ channel expression
in liver and brain tissues of diabetic and nondiabetic mice.
Increased expression of a1G (Cav3.1) and a1H (Cav3.2) subunits
of T-type Ca2+ channels (n=3). The molecular weights of Cav3.1
and Cav3.2 are ,262 kDa. * p,0.05, n =6, compared with WT NS
group. Statistical analyses were performed with ANOVA.
Figure 5 - Immunohistochemical and immunofluorescence stain-
ing showing an increased expression of a1G and a1H subunits of
T-type Ca2+ channels in liver and brain slide preparations. A and
C) Immunohistochemical staining for T-type Ca2+ channel a1G (A)
and a1H (C) subunits in liver slide preparations from non-diabetic
mice (scale bar = 20 mm). B and D) Immunohistochemical staining
of db/db animal liver preparations (scale bar = 20 mm). E and G)
Immunofluorescence staining showing the expression of a1G (E)
and a1H (G) subunits of T-type Ca2+ channels in brain slide
preparations from nondiabetic mice (scale bar = 25 mm). F and H)
Immunofluorescence staining of brain slide preparations from
db/db mice (scale bar = 25 mm).
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antagonists under high insulin concentrations suggests that
the target organs of mibefradil may include the liver and the
brain, which is the upper-level control center for hepatic
glucose production. We examined the protein levels of Cav3.1
(a1G) and Cav3.2 (a1H) a1 subunits of T-type Ca2+ channels
in the liver and brain of db/db mice and control wild-type
mice. As shown in Figure 4, both Cav3.1 and Cav3.2 in the
liver and brain were significantly higher in db/db mice. These
data may explain the difference in the blood glucose-lowering
effects of mibefradil and NNC 55-0396 observed in db/db and
wild-type animals. These findings also suggest that the
targets of mibefradil and NNC 55-0396 are in the liver and
the brain in addition to pancreatic b-cells. Immunohisto-
chemistry confirmed the results of Western blot analysis.
Figure 5 shows that the expression of a1G and a1H was
higher in db/db liver (Figure 5B and 5D) and brain (Figure 5F
and 5H) preparations compared to those in the wild-type
animals.
Because db/db mice are characterized by continual
feeding as a result of a mutation in the leptin receptor, we
Figure 6 - Effects of mibefradil and/or nicardipine on the food consumption, mean blood pressure and heart rate of db/db and
nondiabetic mice. A) Effect of mibefradil injection on the food intake of diabetic and nondiabetic mice. B) Effects of mibefradil and
nicardipine on the mean blood pressure of diabetic and nondiabetic mice. C) Effects of mibefradil and nicardipine on the heart rate of
diabetic and nondiabetic mice. * p,0.05, n =6, compared with WT NS group; ** p,0.05, n=6, compared with NS group of the same
type of mice at the same time. Statistical analyses were performed with Student’s t-test (A) or ANOVA (B and C) according to the
specific application.
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also set up experiments to evaluate the effect of mibefradil
and NNC 55-0396 on the feeding behavior of these animals.
Mibefradil significantly reduced the food consumption of
db/db mice but had no significant effect on the control
animals (Figure 6A). This result also suggests mibefradil has
a central nervous system (CNS) target that may affect the
feeding behavior of the diabetic animals (15,16).
Mibefradil also has antihypertensive effects; thus, we
examined the effects of mibefradil and NNC 55-0396 on the
cardiovascular functions of db/db mice. The mean blood
pressure (MBP) and heart rate after drug injection in the db/
db and wild-type mice showed no significant difference in
MBP (Figure 6B) or heart rate (Figure 6C) among mibefradil-,
NNC 55-0396- and vehicle-treated groups. The physiological
functions of T-type Ca2+ channels in cardiovascular regula-
tion in db/db mice remain unclear.
& DISCUSSION
The db/db mouse is a well-established diabetic rodent
model for studying the mechanisms of hyperglycemia,
hyperinsulinemia, hyperlipidemia and related metabolic
abnormalities. The present study is the first attempt to
utilize this model for characterizing the role of T-type Ca2+
channels in hyperglycemia in vivo. The hallmark of diabetes
mellitus is chronically high fasting blood glucose, resulting
from impaired insulin sensitivity in the peripheral tissues
and defective insulin production by pancreatic b-cells.
Using the db/db model, we showed that T-type Ca2+
channels might be novel therapeutic targets for hyperglyce-
mia and that antagonists of T-type Ca2+ channels might
lower basal glucose by reducing liver glucose output and
decreasing basal insulin release or synthesis by pancreatic
b-cells (Figure 7).
Basal insulin release from pancreatic b-cells may be
controlled by a different mechanism from glucose-stimu-
lated insulin release. Hyperinsulinemia is commonly
observed in pre-diabetic and type 2 diabetic patients.
Chronic exposure to elevated insulin may result in the
development of insulin resistance (23) and, in our opinion,
may also lead to the attenuation of first-phase insulin
release observed in type 2 diabetic patients. Therefore, the
fact that T-type Ca2+ channel antagonists can reduce the
basal insulin is certainly an encouraging result because it
may not have a significant impact on glucose-stimulated
insulin release, which is mostly mediated by the activation
of L-type Ca2+ channels.
We have shown that T-type Ca2+ channel antagonists
significantly reduced basal insulin release in wild-type
animals compared to untreated db/db diabetic animals,
indicating that the basal release of insulin from pancreatic b-
cells might involve a T-type Ca2+ channel-mediated
mechanism. However, residual basal insulin is still elevated
after T-type Ca2+ channel antagonist treatment, suggesting
that T-type Ca2+ channel antagonists may also suppress
glucose output from the liver during fasting.
As shown in Figure 3, the results of ITT indicated that
treatment with T-type Ca2+ channel antagonists failed to
improve glucose disposal in db/db mice compared to
untreated animals. We are currently unable to draw a
definitive conclusion about the effects of these drugs on
improving insulin sensitivity in muscle, adipose or brain
tissue. It is possible that the db/db mouse is not a suitable
model for studying the role of T-type Ca2+ channels in
insulin sensitivity because the hyperglycemia of the db/db
mice cannot be reversed by an injection of insulin (The
Jackson Laboratory, http://jaxmice.jax.org/list/ra66.html).
The overexpression of T-type Ca2+ channel a1G and a1H
subunits in db/db mice compared with the wild-type animals
suggests that either a genetic predisposition favors the T-type
Ca2+ channels or a secondary pathological regulation of these
proteins occurs in these mice. Nevertheless, the fact that T-
type Ca2+ channel antagonists have an effect on glucose
regulation in wild-type animals (Figure 2B) suggests that T-
type Ca2+ channels may also have physiological functions in
non-diabetic animals at low expression levels.
Further investigation is required to confirm the effects of
T-type Ca2+ channel antagonists on metabolic regulation in
the CNS. The results of the present study show an increased
expression of T-type Ca2+ channel a1G and a1H subunits in
the brain of db/db mice, suggesting that these channels may
play critical roles in the mechanisms of hyperglycemia and
hyperlipidemia in these animals. We also show that T-type
Ca2+ channel antagonists caused a decrease in appetite in
the later phases of drug treatment, as well as a decrease in
body weight (data not shown), in db/db mice, indicating that
T-type Ca2+ channels indeed play an important role in
metabolic regulation in db/db mice; nevertheless, further
investigation of this subject is necessary.
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